CD274 and neoplasm: These models are established in immunodeficient mice engrafted with CD34+ hematopoietic stem cells (HSCs), allowing for the characterization of distinct circulating and tumor-infiltrating immune cell profiles, as well as the observation of diverse anti-tumor efficacy of PD-1/PD-L1 ICIs16–18.